Composition
- Each Geriatramine 8 mg Extended Release Capsule contains: Galantamine hydrobromide Extended Release Pellets 100 mg.
- Each 100 mg pellets contain: Galantamine hydrobromide 10.25 mg (equivalent to 8 mg Galantamine).
- Each Geriatramine 16 mg Extended Release Capsule contains: Galantamine hydrobromide Extended Release Pellets 200 mg.
- Each 200 mg pellets contain: Galantamine hydrobromide 20.5 mg (equivalent to 16 mg Galantamine).
|
Indications
Geriatramine is indicated for the symptomatic treatment of mild to moderately severe dementia of the Alzheimer type.
|
Dosage
- Starting dose: The recommended starting dose is 8 mg/day for 4 weeks.
- Maintenance dose: The initial maintenance dose is 16 mg/day and patients should be
maintained on 16 mg/day for at least 4 weeks. An increase to the maintenance dose of 24 mg/day should be considered on an individual basis after appropriate assessment including evaluation of clinical benefit and tolerability. In individual patients not showing an increased response or not tolerating 24 mg/day, a dose reduction to 16 mg/day should be considered.
|
How Supplied
- Geriatramine 8 mg Extended Release Capsules: Carton box containing 1, 2 or 3 (AL / transparent PVC) strips, each of 10 Extended Release Capsules.
- Geriatramine 16 mg Extended Release Capsules: Carton box containing 1, 2 or 3 (AL / transparent Aclar) strips, each of 10 Extended Release Capsules.
|